Display options
Cite
Pantziarka P, Bouche G, Sukhatme V, et al. Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent. Ecancermedicalscience. 2016;10:680doi: 10.3332/ecancer.2016.680.
Pantziarka, P., Bouche, G., Sukhatme, V., Meheus, L., Rooman, I., & Sukhatme, V. P. (2016). Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent. Ecancermedicalscience, 10680. https://doi.org/10.3332/ecancer.2016.680
Pantziarka, Pan, et al. "Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent." Ecancermedicalscience vol. 10 (2016): 680. doi: https://doi.org/10.3332/ecancer.2016.680
Pantziarka P, Bouche G, Sukhatme V, Meheus L, Rooman I, Sukhatme VP. Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent. Ecancermedicalscience. 2016 Oct 12;10:680. doi: 10.3332/ecancer.2016.680. eCollection 2016. PMID: 27899953; PMCID: PMC5102691.
Copy Download .nbib Format: NLM
Share it on

Ecancermedicalscience. 2016 Oct 12;10:680. doi: 10.3332/ecancer.2016.680. eCollection 2016.

Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent.

Ecancermedicalscience

Pan Pantziarka, Gauthier Bouche, Vidula Sukhatme, Lydie Meheus, Ilse Rooman, Vikas P Sukhatme

Affiliations

  1. Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium; The George Pantziarka TP53 Trust, London, UK.
  2. Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium.
  3. GlobalCures, Inc, Newton MA 02459, USA.
  4. Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium; Oncology Research Centre, Vrije Universiteit Brussel, 1090 Brussels, Belgium.
  5. GlobalCures, Inc, Newton MA 02459, USA; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA.

PMID: 27899953 PMCID: PMC5102691 DOI: 10.3332/ecancer.2016.680

Abstract

Propranolol (PRO) is a well-known and widely used non-selective beta-adrenergic receptor antagonist (beta-blocker), with a range of actions which are of interest in an oncological context. PRO displays effects on cellular proliferation and invasion, on the immune system, on the angiogenic cascade, and on tumour cell sensitivity to existing treatments. Both pre-clinical and clinical evidence of these effects, in multiple cancer types, is assessed and summarised and relevant mechanisms of action outlined. In particular there is evidence that PRO is effective at multiple points in the metastatic cascade, particularly in the context of the post-surgical wound response. Based on this evidence the case is made for further clinical investigation of the anticancer effects of PRO, particularly in combination with other agents. A number of trials are on-going, in different treatment settings for various cancers.

Keywords: Propranolol; ReDO project; beta-blockers; drug repurposing

References

  1. Trends Mol Med. 2003 Feb;9(2):73-8 - PubMed
  2. Mol Cancer Res. 2012 Feb;10(2):197-207 - PubMed
  3. Oncogene. 2016 May 5;35(18):2390-7 - PubMed
  4. Cancer Sci. 2014 Jul;105(7):847-56 - PubMed
  5. Cell. 2010 Jul 9;142(1):52-64 - PubMed
  6. Clin Cancer Res. 2003 Oct 1;9(12):4514-21 - PubMed
  7. Brain Behav Immun. 2012 Nov;26(8):1226-38 - PubMed
  8. Oncol Rep. 2016 Sep;36(3):1576-84 - PubMed
  9. Pharmacol Rep. 2014 Dec;66(6):1114-21 - PubMed
  10. World J Gastrointest Oncol. 2015 Apr 15;7(4):17-29 - PubMed
  11. Cochrane Database Syst Rev. 2012 Aug 15;(8):CD007814 - PubMed
  12. Breast Cancer Res Treat. 2015 Nov;154(2):319-28 - PubMed
  13. Curr Mol Med. 2013 Jul;13(6):1023-34 - PubMed
  14. Psychoneuroendocrinology. 2015 Feb;52:130-42 - PubMed
  15. Eur J Clin Invest. 1993 Jan;23(1):46-52 - PubMed
  16. Life Sci. 2000 Mar 31;66(19):1827-38 - PubMed
  17. Int J Cancer. 2012 Jan 1;130(1):59-70 - PubMed
  18. PLoS One. 2013;8(3):e60021 - PubMed
  19. Oncotarget. 2014 Jan 15;5(1):161-72 - PubMed
  20. Nat Rev Immunol. 2005 Mar;5(3):243-51 - PubMed
  21. Pharm Biol. 2014 Nov;52(11):1374-81 - PubMed
  22. Brain Behav Immun. 2012 May;26(4):635-41 - PubMed
  23. Cancer Immunol Immunother. 2014 Nov;63(11):1115-28 - PubMed
  24. J Am Coll Cardiol. 1983 Feb;1(2 Pt 1):492-8 - PubMed
  25. Medicine (Baltimore). 2015 Jul;94(27):e1097 - PubMed
  26. J Cancer Res Clin Oncol. 2013 Feb;139(2):327-35 - PubMed
  27. Pediatr Blood Cancer. 2016 Jul;63(7):1290-2 - PubMed
  28. Cancer Res. 2010 Sep 15;70(18):7042-52 - PubMed
  29. Oncotarget. 2015 May 10;6(13):11264-80 - PubMed
  30. Am J Clin Oncol. 2014 Oct;37(5):473-9 - PubMed
  31. Neuroimmunomodulation. 2015;22(3):138-51 - PubMed
  32. Nat Rev Cancer. 2013 Jul;13(7):511-8 - PubMed
  33. Mod Pathol. 2012 Nov;25(11):1446-51 - PubMed
  34. J Pediatr Surg. 2013 Dec;48(12):2460-5 - PubMed
  35. Sci Signal. 2013 May 28;6(277):pe20 - PubMed
  36. Med Hypotheses. 2014 Aug;83(2):148-50 - PubMed
  37. J Nucl Med. 1986 Feb;27(2):243-5 - PubMed
  38. Ann Surg Oncol. 2003 Oct;10(8):972-92 - PubMed
  39. J Nucl Med. 2014 Mar;55(3):439-45 - PubMed
  40. Mol Biol Cell. 2010 Aug 15;21(16):2916-29 - PubMed
  41. Exp Ther Med. 2015 Sep;10(3):1079-1083 - PubMed
  42. FASEB J. 2016 Mar;30(3):1144-54 - PubMed
  43. J Clin Invest. 1997 Sep 15;100(6):1513-9 - PubMed
  44. J Immunol. 2016 Apr 15;196(8):3460-9 - PubMed
  45. Cancer Biol Ther. 2010 Jul 1;10 (1):19-29 - PubMed
  46. Best Pract Res Clin Anaesthesiol. 2013 Dec;27(4):441-56 - PubMed
  47. Biochem J. 1997 Nov 15;328 ( Pt 1):179-83 - PubMed
  48. Alzheimer Dis Assoc Disord. 2005 Jan-Mar;19(1):23-8 - PubMed
  49. N Engl J Med. 2008 Jun 12;358(24):2649-51 - PubMed
  50. EMBO J. 2015 Sep 2;34(17):2219-36 - PubMed
  51. Cancer Causes Control. 2004 Aug;15(6):535-41 - PubMed
  52. FEBS J. 2014 May;281(9):2172-89 - PubMed
  53. PLoS Biol. 2012 Jul;10(7):e1001363 - PubMed
  54. Jpn J Pharmacol. 1969 Jun;19(2):275-81 - PubMed
  55. Neuroimmunomodulation. 2013;20(1):1-8 - PubMed
  56. PLoS One. 2012;7(1):e29915 - PubMed
  57. PLoS One. 2013;8(3):e59319 - PubMed
  58. Psychol Bull. 2004 Jul;130(4):601-30 - PubMed
  59. Iran Biomed J. 2009 Oct;13(4):223-8 - PubMed
  60. J Biol Chem. 2012 Jan 2;287(1):712-22 - PubMed
  61. Cancer Lett. 1986 Mar;30(3):251-9 - PubMed
  62. Int J Cancer. 2006 Jun 1;118(11):2744-9 - PubMed
  63. Br J Anaesth. 2014 Jul;113 Suppl 1:i82-7 - PubMed
  64. Nat Rev Clin Oncol. 2015 Apr;12(4):213-26 - PubMed
  65. Med Hypotheses. 2013 Oct;81(4):707-12 - PubMed
  66. Br J Cancer. 2013 Jun 25;108(12):2485-94 - PubMed
  67. Clin Sci Mol Med. 1978 Jul;55(1):23-9 - PubMed
  68. FEBS Lett. 1990 Dec 17;277(1-2):7-10 - PubMed
  69. Crit Rev Oncol Hematol. 2011 Nov;80(2):257-63 - PubMed
  70. Pancreatology. 2016 May-Jun;16(3):423-33 - PubMed
  71. J Mol Med (Berl). 2013 Dec;91(12):1407-19 - PubMed
  72. N Engl J Med. 2015 Feb 19;372(8):735-46 - PubMed
  73. FEBS Lett. 1984 Apr 24;169(2):151-5 - PubMed
  74. Cancer Treat Rev. 2016 Jun;47:1-11 - PubMed
  75. PLoS One. 2013 Sep 18;8(9):e74497 - PubMed
  76. Clin Cancer Res. 2009 Apr 15;15(8):2695-702 - PubMed
  77. Ecancermedicalscience. 2016 Jan 11;10:610 - PubMed
  78. Crit Care. 2015 May 04;19:217 - PubMed
  79. Cancer Biol Ther. 2015;16(9):1364-74 - PubMed
  80. Nat Rev Cancer. 2015 Sep;15(9):563-72 - PubMed
  81. Eur J Cancer Prev. 2016 Sep;25(5):440-8 - PubMed
  82. Radiat Oncol. 2010 Oct 26;5:98 - PubMed
  83. Int J Cancer. 2004 Nov 1;112(2):231-8 - PubMed
  84. Brain Behav Immun. 2013 Mar;30 Suppl:S32-40 - PubMed
  85. J Cell Physiol. 2016 Feb;231(2):459-72 - PubMed
  86. Oncogene. 2016 Jan 7;35(1):47-58 - PubMed
  87. Br J Cancer. 1984 Oct;50(4):501-7 - PubMed
  88. J Clin Invest. 2014 Mar;124(3):922-8 - PubMed
  89. Hepatogastroenterology. 2012 Mar-Apr;59(114):584-8 - PubMed
  90. Br J Pharmacol. 2012 May;166(2):721-36 - PubMed
  91. Ecancermedicalscience. 2016 Apr 05;10:631 - PubMed
  92. J Clin Med Res. 2009 Aug;1(3):144-9 - PubMed
  93. Int J Oncol. 1997 Jun;10(6):1197-201 - PubMed
  94. Br J Cancer. 1987 Nov;56(5):585-8 - PubMed
  95. Ecancermedicalscience. 2014 Nov 26;8:485 - PubMed
  96. Thromb Haemost. 2009 Aug;102(2):258-67 - PubMed
  97. Onco Targets Ther. 2010 Nov 15;3:219-26 - PubMed
  98. Front Cell Dev Biol. 2015 Feb 02;3:4 - PubMed
  99. Stroke. 1978 Jul-Aug;9(4):344-9 - PubMed
  100. Brain Behav Immun. 1992 Jun;6(2):170-8 - PubMed
  101. Semin Immunopathol. 2013 Mar;35(2):123-37 - PubMed
  102. Eur J Cancer. 2000 Feb;36(3):330-4 - PubMed
  103. J Immunol. 1998 Apr 1;160(7):3251-8 - PubMed
  104. Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):151-9 - PubMed
  105. Biochem Pharmacol. 2015 Sep 15;97(2):147-57 - PubMed
  106. Br J Clin Pharmacol. 2014 Nov;78(5):940-9 - PubMed
  107. Psychooncology. 2013 Aug;22(8):1889-94 - PubMed
  108. Iran J Immunol. 2013 Jun;10(2):70-82 - PubMed
  109. J Pediatr Hematol Oncol. 2011 May;33(4):e171-3 - PubMed
  110. Matrix Biol. 2015 May-Jul;44-46:200-6 - PubMed
  111. Br J Clin Pharmacol. 1986 May;21(5):529-32 - PubMed
  112. J Cancer Res Ther. 2014 Oct-Dec;10(4):998-1003 - PubMed
  113. J Auton Nerv Syst. 1985 Dec;14(4):397-401 - PubMed
  114. J Cancer Res Clin Oncol. 2016 Feb;142(2):423-35 - PubMed
  115. Oncol Rep. 2015 May;33(5):2513-20 - PubMed
  116. J Otolaryngol Head Neck Surg. 2012 Oct;41(5):334-44 - PubMed
  117. Brain Behav Immun. 2014 Aug;40:40-7 - PubMed
  118. Medicine (Baltimore). 2015 Nov;94(45):e0897-0 - PubMed
  119. J Pathol. 2010 Sep;222(1):1-15 - PubMed
  120. Breast Cancer Res Treat. 2012 Jul;134(2):881-8 - PubMed
  121. Br J Pharmacol. 2011 Feb;162(3):712-21 - PubMed
  122. PLoS One. 2013 Apr 09;8(4):e61435 - PubMed
  123. Ecancermedicalscience. 2015 Jan 08;9:499 - PubMed
  124. Int J Cancer. 2011 May 15;128(10):2306-16 - PubMed
  125. Pancreas. 2009 Jan;38(1):94-100 - PubMed
  126. Gene. 2006 Jan 17;366(1):2-16 - PubMed
  127. Life Sci. 1990;47(10):869-76 - PubMed
  128. Br J Cancer. 1987 Aug;56(2):127-32 - PubMed
  129. Brain Behav Immun. 2011 Mar;25(3):574-83 - PubMed
  130. J Immunol. 1999 Sep 1;163(5):2492-9 - PubMed
  131. Clin Exp Immunol. 2005 Jan;139(1):25-34 - PubMed
  132. Tumour Biol. 2016 Feb;37(2):1387-406 - PubMed
  133. J Cardiovasc Pharmacol. 1990;16 Suppl 5:S76-80 - PubMed
  134. J Clin Med. 2016 Jan 27;5(2):null - PubMed
  135. Mol Cancer Res. 2012 Feb;10(2):239-49 - PubMed
  136. Dermatoendocrinol. 2015 Jan 26;6(1):e979699 - PubMed
  137. Gastric Cancer. 2016 Jul;19(3):817-26 - PubMed
  138. Mol Pharmacol. 1988 Apr;33(4):454-62 - PubMed
  139. Tohoku J Exp Med. 2013;229(1):61-6 - PubMed
  140. Ann Surg Oncol. 2013 Dec;20 Suppl 3:S650-60 - PubMed
  141. Nat Rev Cancer. 2008 Nov;8(11):835-50 - PubMed
  142. Jpn J Cancer Res. 2002 Jul;93(7):729-35 - PubMed
  143. Vascul Pharmacol. 2010 Nov-Dec;53(5-6):200-8 - PubMed
  144. Br J Clin Pharmacol. 1984;17 Suppl 1:51S-57S - PubMed
  145. Croat Med J. 2005 Apr;46(2):219-24 - PubMed
  146. EBioMedicine. 2016 Apr;6:87-95 - PubMed
  147. Clin Breast Cancer. 2015 Dec;15(6):426-31 - PubMed
  148. Sci Signal. 2013 May 28;6(277):ra39 - PubMed
  149. Lab Invest. 2013 Mar;93(3):279-90 - PubMed
  150. J Invest Dermatol. 2015 Feb;135(2):525-31 - PubMed
  151. Ann Surg. 2011 Apr;253(4):798-810 - PubMed
  152. Nat Rev Cancer. 2009 Apr;9(4):285-93 - PubMed
  153. Clin Cancer Res. 2015 Nov 15;21(22):5064-72 - PubMed
  154. JAMA Otolaryngol Head Neck Surg. 2013 Oct;139(10):1026-31 - PubMed
  155. Int J Cardiol. 2015 Apr 1;184:9-13 - PubMed
  156. Ann Surg Oncol. 2011 Oct;18(10):2946-51 - PubMed
  157. Cancer Res. 1984 Oct;44(10):4303-7 - PubMed
  158. Immunol Cell Biol. 2013 Sep;91(8):493-502 - PubMed
  159. Oncotarget. 2011 Oct;2(10):797-809 - PubMed
  160. Exp Cell Res. 1965 Mar;37:662-79 - PubMed
  161. Br J Anaesth. 2012 Dec;109 Suppl 1:i17-i28 - PubMed
  162. Cancer Biother Radiopharm. 2010 Jun;25(3):317-23 - PubMed
  163. Carcinogenesis. 1989 Sep;10(9):1753-5 - PubMed
  164. Nat Rev Cancer. 2011 Feb;11(2):123-34 - PubMed
  165. Brain Behav Immun. 2012 Nov;26(8):1224-5 - PubMed
  166. Science. 1961 Jan 6;133(3445):44-5 - PubMed
  167. J Nerv Ment Dis. 1986 May;174(5):290-4 - PubMed
  168. J Transl Med. 2013 Mar 22;11:72 - PubMed
  169. Clin Exp Metastasis. 2013 Jan;30(1):47-68 - PubMed
  170. J Clin Oncol. 2011 Jul 1;29(19):2635-44 - PubMed
  171. Cancer Prev Res (Phila). 2012 Aug;5(8):1007-14 - PubMed
  172. Cancer Res. 2001 Apr 1;61(7):2866-9 - PubMed
  173. Clin Pharmacol Ther. 1981 Dec;30(6):790-5 - PubMed
  174. Pharmacol Res. 2009 Nov;60(5):438-45 - PubMed
  175. Clin Cancer Res. 2014 Aug 1;20(15):4096-106 - PubMed
  176. Cancer Res. 2006 Nov 1;66(21):10357-64 - PubMed
  177. Psychoneuroendocrinology. 2013 Sep;38(9):1698-708 - PubMed
  178. Nat Commun. 2016 Mar 01;7:10634 - PubMed
  179. Int J Oncol. 2015 Aug;47(2):527-34 - PubMed
  180. JAMA Dermatol. 2015 Nov;151(11):1226-9 - PubMed
  181. FEBS Lett. 1999 Jan 15;442(2-3):167-72 - PubMed
  182. Br J Clin Pharmacol. 1980 Jan;9(1):33-40 - PubMed
  183. Nat Med. 2006 Aug;12 (8):939-44 - PubMed
  184. Orphanet J Rare Dis. 2015 Sep 22;10:118 - PubMed
  185. Brain Behav Immun. 2009 Feb;23(2):267-75 - PubMed
  186. Cancer Biomark. 2013;13(3):145-54 - PubMed
  187. Oncol Rep. 2010 Dec;24(6):1669-76 - PubMed
  188. Eur Surg Res. 2013;50(1):14-23 - PubMed
  189. FEBS Lett. 1977 Apr 15;76(2):302-5 - PubMed
  190. Cancer. 2002 Aug 15;95(4):808-15 - PubMed
  191. Oncol Rep. 2009 Oct;22(4):825-30 - PubMed
  192. Ann Surg Oncol. 2008 Jul;15(7):2042-52 - PubMed
  193. Nat Rev Clin Oncol. 2016 Oct;13(10):611-26 - PubMed
  194. Brain Behav Immun. 2013 Mar;30 Suppl:S1-9 - PubMed
  195. Clin Cancer Res. 2006 Jan 15;12(2):369-75 - PubMed
  196. Breast Cancer Res. 2015 Nov 25;17(1):145 - PubMed
  197. Asian Pac J Cancer Prev. 2014;15(3):1085-91 - PubMed
  198. J Immunol. 2010 Mar 1;184(5):2449-57 - PubMed
  199. Postgrad Med J. 1976;52 Suppl 4:22-25 - PubMed
  200. Anesth Analg. 2010 Jun 1;110(6):1636-43 - PubMed
  201. N Engl J Med. 2011 Apr 7;364(14 ):1380-2 - PubMed

Publication Types